SCHEMBL3618362

SCHEMBL3618362

Cc1nnc(Cl)c(-c2c(F)cc(F)cc2F)c1-c1cccs1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 4/20 0.34
TSHR P16473 3/20 0.34
RAB9A P51151 5/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
NPC1 O15118 4/20 0.34
HSD17B10 Q99714 2/20 0.34
HPGD P15428 1/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MAPT P10636 2/20 0.33
GABRP O00591 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610666 0.90 MAPT (0.37) KDM4EMEN1CYP1A2GAACYP2C9
SCHEMBL3608511 0.86 MAPT (0.35) KDM4EMEN1CYP1A2GAACYP2C9
SCHEMBL3618629 0.82 RPS6KB2 (0.36) KDM4EMEN1CYP1A2GAACYP2C9
SCHEMBL4582844 0.81 HSD11B1 (0.41) KDM4EMEN1CYP1A2GAACYP2C9
SCHEMBL3614591 0.80 GABRP (0.33) ALDH1A1TSHRRAB9AHSD17B10MAPT
SCHEMBL29356089 0.77 MAOB (0.40) KDM4EMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL2347918 0.77 MAOB (0.40) KDM4EMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL3622023 0.76 KDR (0.35) CASP1
SCHEMBL2354401 0.76 MEN1 (0.35) MEN1CYP1A2KMT2ATSHRRAB9A
SCHEMBL4610692 0.75 ALDH1A1 (0.37) KDM4EMEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US claimed
EP-2041113-A1 NOVEL PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-04-01 EP claimed
WO-2008009406-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-01-24 WO claimed
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US disclosed
EP-2041113-A1 NOVEL PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-04-01 EP disclosed
WO-2008009406-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES C3AR1, CBR3, C5 KDM4E 2526/4885MEN1 3202/4885CYP1A2 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.